Research Article Details

Article ID: A15667
PMID: 28776153
Source: Obes Surg
Title: Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.
Abstract: BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), are endemic in obesity. We aimed to evaluate the diagnostic accuracy and reproducibility of a simple intraoperative visual liver score to stratify the risk of NASH and NAFLD in obesity and determine the need for liver biopsy. METHODS: This is a prospective cohort study of obese adults undergoing bariatric surgery. The surgical team used a visual liver score to evaluate liver colour, size and surface. This was compared to histology from an intraoperative liver biopsy. RESULTS: There were 152 participants, age 44.6&#160;&#177;&#160;12&#160;years, BMI 45&#160;&#177;&#160;8.3&#160;kg/m2. Prevalence of NAFLD was 70.4%, with 12.1% NASH and 26.4% borderline NASH. Single-visual components were less accurate than total composite score. Steatosis was most accurately identified (significant steatosis: AUROC 0.746, p&#160;<&#160;0.05; severe steatosis: AUROC 0.855, p&#160;<&#160;0.05). NASH was identified with moderate accuracy (AUROC 0.746, p&#160;=&#160;0.001), with sensitivity 75% for a score &#8805;&#160;2. Stratification into low (&#8804;&#160;1) and high-risk (&#8805;&#160;4) scores accurately identified patients who should or should not have an intraoperative biopsy. Most patients with a normal-appearing liver did not have disease (94.4%). The structured visual assessment was quick and interobserver agreement was reasonable (&#954;&#160;=&#160;0.53, p&#160;<&#160;0.05). CONCLUSIONS: A simple, structured tool based on liver appearance can be a useful and reliable tool for NAFLD risk stratification and identification of patients who would most and least benefit from a biopsy. A normal liver appearance reliably excludes significant liver disease, avoiding the need for liver biopsy in patients otherwise at high clinical risk of NASH.
DOI: 10.1007/s11695-017-2859-3